Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks cholesterol drug inclisiran in heart patients

NCT ID NCT06958315

Ongoing Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This observational study follows about 198 patients in Spain who are already taking inclisiran (Leqvio) for high cholesterol linked to heart disease or a genetic condition. Researchers will check if patients reach their LDL cholesterol goals after 6 and 12 months. The goal is to see how the drug performs in everyday practice, outside of strict clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Inclisiran (Leqvio)
What this could lead to
If successful, this study could show how well inclisiran works in everyday clinical practice, helping doctors better manage high cholesterol in patients with heart disease or genetic cholesterol disorders.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test new treatments or prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease familial hypercholesterolemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC VASCULAR DISEASE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

  • Novartis Investigative Site

    Cadiz, Andalusia, 11009, Spain

  • Novartis Investigative Site

    Granada, Andalusia, 18014, Spain

  • Novartis Investigative Site

    Huelva, Andalusia, 21005, Spain

  • Novartis Investigative Site

    Jaén, Andalusia, 23007, Spain

  • Novartis Investigative Site

    Marbella, Andalusia, 29600, Spain

  • Novartis Investigative Site

    Mallorca, Balearic Islands, 07198, Spain

  • Novartis Investigative Site

    Puerto Real, Cadiz, 11510, Spain

  • Novartis Investigative Site

    Santander, Cantabria, 39008, Spain

  • Novartis Investigative Site

    Andújar, Jaen, 23740, Spain

  • Novartis Investigative Site

    Logroño, La Rioja, 26006, Spain

  • Novartis Investigative Site

    San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320, Spain

  • Novartis Investigative Site

    Burgos, 09006, Spain

  • Novartis Investigative Site

    Córdoba, 14004, Spain

  • Novartis Investigative Site

    Fuerteventura, 35600, Spain

  • Novartis Investigative Site

    Las Palmas GC, 35010, Spain

  • Novartis Investigative Site

    León, 24080, Spain

  • Novartis Investigative Site

    Málaga, 29010, Spain

  • Novartis Investigative Site

    Salamanca, 37007, Spain

  • Novartis Investigative Site

    Seville, 41009, Spain

  • Novartis Investigative Site

    Seville, 41013, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.